Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 2/20 | 1.00 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.57 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16969508 | 0.85 | MERTK (0.73) | MERTKVCAM1LRRK2L3MBTL1MAPT | |
| SCHEMBL2904358 | 0.83 | MERTK (0.71) | MERTKVCAM1LRRK2L3MBTL1MAPT | |
| SCHEMBL2904234 | 0.81 | MERTK (0.68) | MERTKL3MBTL1MAPTCXCR2KMT2A | |
| SCHEMBL11528308 | 0.81 | MERTK (0.68) | MERTKL3MBTL1MAPTCXCR2KMT2A | |
| SCHEMBL11876938 | 0.81 | MERTK (0.68) | MERTKL3MBTL1MAPTCXCR2KMT2A | |
| SCHEMBL11549542 | 0.81 | L3MBTL1 (0.68) | MERTKL3MBTL1MAPTCXCR2KMT2A | |
| SCHEMBL3743290 | 0.78 | MERTK (0.64) | MERTKVCAM1LRRK2L3MBTL1MAPT | |
| SCHEMBL2902330 | 0.78 | MAPT (0.65) | MERTKL3MBTL1MAPTKMT2AMEN1 | |
| SCHEMBL25295620 | 0.78 | MERTK (0.64) | MERTKVCAM1LRRK2L3MBTL1MAPT | |
| SCHEMBL15286174 | 0.78 | MERTK (0.64) | MERTKVCAM1LRRK2L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2213650-B1 | SUBSTITUTED DIPHENYLAMINES AS INHIBITORS OF REVERSE TRANSCRIPTASE, PROCESS OF PREPARING THEM AND USE THEREOF | INST PHARM & TOXICOLOGY AMMS (CN) | 2015-08-12 | — | — | EP | disclosed |
| US-8309602-B2 | Multi-substituted diarylanilines as non-nucleoside HIV reverse transcriptase inhibitors, and preparation and use thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY (CN) | 2012-11-13 | — | — | US | disclosed |
| US-20100292324-A1 | Multi-Substituted Diarylanilines as Non-Nucleoside HIV Reverse Transcriptase Inhibitors, and Preparation and Use Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2010-11-18 | — | — | US | disclosed |
| EP-2213650-A1 | SUBSTITUTED DIPHENYLAMINES AS INHIBITORS OF REVERSE TRANSCRIPTASE, PROCESS OF PREPARING THEM AND USE THEREOF | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China (CN) | 2010-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292324-A1 | Multi-Substituted Diarylanilines as Non-Nucleoside HIV Reverse Transcriptase Inhibitors, and Preparation and Use Thereof | PNP, POLRMT, QTRT1 | MERTK 3429/4885VCAM1 2953/4885LRRK2 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.